Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme
 
  • Details

The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme

Resource
Oncology, 84(6), 326-335
Journal
Oncology
Pages
326-335
Date Issued
2013
Date
2013
Author(s)
Lee P.-Y.
Chen C.-L.
ZHONG-ZHE LIN  
ANN-LII CHENG  
Chen E.I.-T.
Whang-Peng J.
Huang C.-Y.F.
DOI
10.1159/000347021
URI
http://ntur.lib.ntu.edu.tw//handle/246246/259371
Abstract
Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10% of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50% inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM. Copyright (c) 2013 S. Karger AG, Basel
Subjects
Glioblastoma multiforme
VE-465
Brain tumor
SDGs

[SDGs]SDG3

Other Subjects
antineoplastic agent; aurora kinase; aurora kinase inhibitor; caspase 3; caspase 8; caspase 9; protein p53; unclassified drug; ve 465; antineoplastic activity; Article; breast carcinoma; cancer inhibition; cell cycle progression; cell division; cell fractionation; cell growth; cell shape; cell survival; cell viability; colony formation; concentration (parameters); controlled study; cytotoxicity; down regulation; drug exposure; drug sensitivity; endoreduplication; enzyme activation; enzyme activity; enzyme inhibition; glioblastoma; growth inhibition; human; human cell; IC50; in vitro study; priority journal; protein expression; protein phosphorylation; protein protein interaction; signal transduction; upregulation
File(s)
Loading...
Thumbnail Image
Name

index.html

Size

23.15 KB

Format

HTML

Checksum

(MD5):71caa92bf5b45edc905f9c69462be26f

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science